LoadingLoadingLoadingThe quick read
Latest quote
Net selling: insiders sold $437K and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $437K and bought $0 of BMY stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Massacesi, Cristian (EVP,Chief Med Offr,Head of Dev), who sold $403K. The latest filing was on Sep 10, 2026.
Rep. Mike Kelly (R) sold $15K to $50K on May 7, 2026, disclosed 35 days later. In total, 1 member disclosed 1 BMY trade with trade dates in the last 180 days, filed a median 35 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Sells/Trims (3)
Millennium
$353.6M
trimmed
Point72
$32.2M
sold
Susquehanna
$25.7M
trimmed
Sells (1)
No tracked top-trader positions in BMY right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Adjusted EPS
$1.60 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $2.04 / $1.60Yahoo Finance | +27.74% beat | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $1.58 / $1.42Yahoo Finance | +11.18% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 5, 2026 | $1.26 / $1.20Yahoo Finance | +4.57% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $1.63 / $1.52Yahoo Finance | +7.55% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $1.46 / $1.10Alpha Vantage | +32.73% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 24, 2025 | $1.80 / $1.50Alpha Vantage | +20.00% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 6, 2025 | $1.67 / $1.47Alpha Vantage | +13.61% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | $1.80 / $1.50Alpha Vantage | +20.00% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 17, 2026
EPS expected
$0.98 to $1.87
Revenue expected
20 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $12.22B | $12.50B | $11.49B | $12.97B |
| Cost of what it sold | $3.44B | $4.10B | $3.42B | $3.73B |
| Gross profit | $8.79B | $8.41B | $8.07B | $9.25B |
| What it spent | ||||
| Research and development | $2.53B | $2.59B | $2.65B | $2.96B |
| Sales and admin | $1.79B | $2.18B | $1.62B | $1.83B |
| Other operating costs | $831.0M | $826.0M | $437.0M | $437.0M |
| Total operating expenses | $5.15B | $5.59B | $4.70B | $5.22B |
| What was left | ||||
| Operating profit | $3.64B | $2.81B | $3.37B | $4.03B |
| Interest on debt | $480.0M | $432.0M | $411.0M | $407.0M |
| Profit before tax | $3.11B | $1.47B | $3.24B | $4.09B |
| Tax | $919.0M | $384.0M | $561.0M | $770.0M |
| Net profit | $2.20B | $1.09B | $2.68B | $3.32B |
| EBITDA | $4.61B | $2.88B | $4.25B | $5.09B |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
RBC keeps USD 56.00 target for Alkermes stock
NeutralOct 15UBS lifts PTC Therapeutics stock target to USD 90.00
NeutralOct 15Is Cytokinetics (CYTK) Undervalued As New Aficamten Phase 3 Data Supports Expansion?
NeutralOct 15ANKTIVA + BCG Gains Expanded FDA Approval for BCG-Unresponsive NMIBC - ImmunityBio
NeutralOct 15Bristol, AbbVie Seek Intervention in Suit Over Drug Rebate Pilot
NeutralOct 15Bristol, AbbVie Seek Intervention in Suit Over Drug Rebate Pilot
Leans bearishOct 15Bristol Myers Squibb Company $BMY Stock: Curated Wealth Partners LLC Cuts Position
NeutralOct 15Mixed Trial Results Might Change The Case For Investing In Bristol Myers Squibb (BMY)
NeutralOct 15